inclusion criteria: willing and able to provide informed consent. males and females of ≥ 18 years of age patient with mild covid-19 infection having ≥ 1 symptoms. laboratory confirmed covid-19 infection by reverse transcription polymerase chain reaction (rt-pcr) in nasopharyngeal sample (within 72 hours prior to randomization). patient should have at least one pre-existing high-risk feature for developing severe covid-19 illness. ability to swallow and retain oral medication. male patient who is surgically sterile, or who is willing to agree to use a contraceptive measure. women of childbearing potential should be willing to use a medically acceptable method of contraception. willing to receive telephone calls or have videoconferences with study team personnel. willing and able to understand the nature of this study, comply with the study procedures and follow-up procedures as per the study protocol.

inclusion criteria: willing and able to provide informed consent. males and females of ≥ 18 years of age patient with mild covid-19 infection having ≥ 1 symptoms. laboratory confirmed covid-19 infection by reverse transcription polymerase chain reaction (rt-pcr) in nasopharyngeal sample (within 72 hours prior to randomization). patient should have at least one pre-existing high-risk feature for developing severe covid-19 illness. ability to swallow and retain oral medication. male patient who is surgically sterile, or who is willing to agree to use a contraceptive measure. women of childbearing potential should be willing to use a medically acceptable method of contraception. willing to receive telephone calls or have videoconferences with study team personnel. willing and able to understand the nature of this study, comply with the study procedures and follow-up procedures as per the study protocol.

inclusion criteria: 1. willing and able to provide informed consent. 2. males and females of ≥ 18 years of age 3. patient with mild covid-19 infection having ≥ 1 symptoms. 4. laboratory confirmed covid-19 infection by reverse transcription polymerase chain reaction (rt-pcr) in nasopharyngeal sample (within 72 hours prior to randomization). 5. patient should have at least one pre-existing high-risk feature for developing severe covid-19 illness. 6. ability to swallow and retain oral medication. 7. male patient who is surgically sterile, or who is willing to agree to use a contraceptive measure. 8. women of childbearing potential should be willing to use a medically acceptable method of contraception. 9. willing to receive telephone calls or have videoconferences with study team personnel. 10. willing and able to understand the nature of this study, comply with the study procedures and follow-up procedures as per the study protocol.

inclusion criteria: 1. willing and able to provide informed consent. 2. males and females of ≥ 18 years of age 3. patient with mild covid-19 infection having ≥ 1 symptoms. 4. laboratory confirmed covid-19 infection by reverse transcription polymerase chain reaction (rt-pcr) in nasopharyngeal sample (within 72 hours prior to randomization). 5. patient should have at least one pre-existing high-risk feature for developing severe covid-19 illness. 6. ability to swallow and retain oral medication. 7. male patient who is surgically sterile, or who is willing to agree to use a contraceptive measure. 8. women of childbearing potential should be willing to use a medically acceptable method of contraception. 9. willing to receive telephone calls or have videoconferences with study team personnel. 10. willing and able to understand the nature of this study, comply with the study procedures and follow-up procedures as per the study protocol.